Table 1.
Effects of pasireotide and active control on GH, IGF-1, and IGFBP-3 after 24 weeks of treatment in all patients
| N a | Baseline geometric mean for all patients (95 % CI) | Baseline geometric mean for responders (95 % CI) | Baseline geometric mean for non-responders (95 % CI) | Week 24 geometric mean for all patients (95 % CI) | Median (IQR) change from baseline to week 24 for all patients (%) | |
|---|---|---|---|---|---|---|
| Pasireotide 40 mg | ||||||
| GH (ng/mL) | 59 | 7.9 (6.0–10.3) | 6.2 (4.2–9.0) | 8.3 (6.1–11.4) | 3.6 (2.5–5.3) | −51.4 (39.8) |
| IGF-1 (ng/mL) | 59 | 640.7 (586.1–700.3) | 462.1 (391.6–545.3) | 684.8 (625.2–750.1) | 400.1 (335.3–477.3) | −38.6 (54.9) |
| IGFBP-3 (µg/mL) | 59 | 6.4 (6.1–6.6) | 5.9 (5.4–6.6) | 6.5 (6.2–6.7) | 5.6 (5.2–5.9) | −13.5 (22.1) |
| Pasireotide 60 mg | ||||||
| GH (ng/mL) | 57 | 6.7 (5.2–8.7) | 4.5 (3.3–6.1) | 7.6 (5.5–10.4) | 2.4 (1.7–3.5) | −61.3 (43.0) |
| IGF-1 (ng/mL) | 57 | 635.7 (582.5–693.8) | 567.9 (484.1–666.3) | 657.3 (593.7–727.6) | 319.1 (266.1–382.6) | −48.9 (42.2) |
| IGFBP-3 (µg/mL) | 57 | 6.1 (5.9–6.4) | 6.0 (5.5–6.6) | 6.2 (5.9–6.5) | 5.2 (4.8–5.6) | −13.2 (21.1) |
| Pasireotide 40/60 mg | ||||||
| GH (ng/mL) | 116 | 7.3 (6.0–8.8) | 5.1 (4.0–6.6) | 7.9 (6.4–9.9) | 3.0 (2.3–3.9) | −55.8 (45.6) |
| IGF-1 (ng/mL) | 116 | 638.2 (599.8–679.2) | 519.2 (460.1–586.0) | 671.6 (627.7–718.7) | 358.0 (315.1–406.8) | −44.3 (48.7) |
| Active control | ||||||
| GH (ng/mL) | 65 | 6.9 (5.7–8.2) | – | – | 5.3 (4.1–6.8) | −14.7 (52.7) |
| IGF-1 (ng/mL) | 65 | 648.5 (594.3–707.7) | – | – | 561.1 (508.2–619.5) | −7.4 (32.3) |
| IGFBP-3 (µg/mL) | 65 | 6.3 (6.1–6.6) | – | – | 5.9 (5.6–6.2) | −5.2 (18.1) |
CI confidence interval, IQR interquartile range
aNumber of patients with baseline measurements